Inhibitors of monocarboxylate transport
OwnerMichael Sullivan, Clare Margaret Murray +6inventors
InventorsMichael Sullivan, Clare Margaret Murray, Raymond Hutchinson, David Keith Donald, Clive Geoffrey Jackson, Andrew Paul Jackson, John Raymond Bantick, Ian David Cook
Life of this patent
Estimating the term…
Abstract
Methods of screening compounds for their ability to inhibit monocarboxylate transport, and methods of making and using such inhibitors to treat disorders associated with cellular proliferation, e.g., immune-mediated disorders and cancer.
Claims45
A method for identifying a compound having therapeutic potential, the method comprising
- (a) determining whether a test compound decreases monocarboxylate transport activity;
- and
- (b) if the compound decreases said activity, identifying the compound as having therapeutic potential.
A method for identifying a compound having therapeutic potential, the method comprising
- (a) determining whether a test compound binds to a monocarboxylate transport protein;
- and
- (b) if the compound binds to the protein, identifying the compound as having therapeutic potential.
A method of treating a human subject in need of treatment for a disease or condition characterised by T-cell activation or cellular proliferation, the method comprising administering to the subject a compound that inhibits cellular monocarboxylate transporter activity, other than a quinazolinedione compound or a compound of formulae I to IX.
A method of treating a human subject in need of treatment for an immune-mediated disorder or cancer, the method comprising administering to the subject a compound that inhibits cellular monocarboxylate transporter activity, provided that the compound is other than a quinazolinedione compound or a compound of formulae I to IX.
A method of treating a human subject in need of treatment for an immune-mediated disorder or cancer, the method comprising identifying a subject as being in need of said treatment, and administering to the subject a compound that inhibits a monocarboxylate transporter other than MCT1 or MCT2.
A method of treating a patient suffering from or likely to suffer from an immune-mediated disorder or cancer, the method comprising (i) identifying a compound as being an inhibitor of monocarboxylate transport in a cell, and (ii) administering to the patient an effective amount of the compound.
A method for treating a patient suffering from an immune-mediated disorder or cancer, the method comprising administering to said patient an effective amount of a compound that specifically reduces expression of an MCT, the compound being selected from the group consisting of an anti-sense molecule, a ribozyme molecule, an RNAi molecule and a triple helix forming molecule.
A method of inhibiting T-cell or B-cell proliferation in a human, the method comprising identifying a human in need of such inhibition, and administering to the human a compound capable of specifically inhibiting monocarboxylate transport within a T-cell or B-cell.
Dependencies are inferred from the claim text.